Send Enquiry      
Global Locations

Sodium valproate

CS-O-02302 Available for Dispatch by 5-Jul-2022

Sodium valproate

CS-O-02302
API Standards

Available for Dispatch by 5-Jul-2022
This Product is a Controlled Substance.
For exact pricing and delivery please contact sales@clearsynth.com

PRODUCT INFO

Compound : Sodium valproate
CAT No. : CS-O-02302
Parent API : Valproic Acid
CAS No. : 1069-66-5
Category : API Standards
Mol. Weight: 166.19
Mol. Formula : C8H15NaO2
Controlled Substance : YES
Purity : Not less than 95 %
Therapeutic : Anticonvulsants (Anti-Epileptics)
Appearance : White to off white solid
USAGE
Application : "Valproate Sodium is the sodium salt form of valproic acid with anti-epileptic activity. Valproate sodium is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, valproate sodium increases conc"
References : "Chang; Z,L,; et al,: Anal, Profiles Drug Subs,; 8; 529 (1979); Della Pachoa; O,E,; et al,: Br, J, Pharmcol,; 125; 1610 (1998); Grimes;c,A,; et al,: J, Neirchem,; 73; 1384 (1999); Locher; W,; Prog, Neurobiol,; 58; 31 (1999);"
SHIPPING INFO
Custom Duty : Applicable
Documents:  View Sample COA   View Sample MSDS
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
PAYMENT INFO
Taxes : Not Applicable
Refund Policy : 30-days money back

More information about Valproic Acid


Valproate (VPA) and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.

Common side effects of valproate include nausea, vomiting, sleepiness, and dry mouth. Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended. Other serious risks include pancreatitis and an increased suicide risk. Valproate is known to cause serious abnormalities in babies if taken during pregnancy, and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition. As of 2022 the drug was still prescribed in the UK to potentially pregnant women, but use declined by 51% from 2018\u201319 to 2020\u201321.

Valproate's precise mechanism of action is unclear. Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, and inhibiting histone deacetylases. Valproic acid is a branched short-chain fatty acid (SCFA) made from valeric acid.

Valproate was first made in 1881 and came into medical use in 1962. It is on the World Health Organization's List of Essential Medicines and is available as a generic medication. In 2019, it was the 114th most commonly prescribed medication in the United States, with more than 5\u00a0million prescriptions.


Related products

Looking for a discounted price or need more info for 'Sodium valproate (CS-O-02302)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Sodium valproate (CS-O-02302)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.